Dashboard
High Debt Company with a Debt to Equity ratio (avg) at 12.05 times
- Poor long term growth as Net Sales has grown by an annual rate of -4.53% and Operating profit at 65.08% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 12.05 times
- The company has been able to generate a Return on Capital Employed (avg) of 12.08% signifying low profitability per unit of total capital (equity and debt)
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
With ROCE of 28.4, it has a Attractive valuation with a 3.4 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 152 Cr (Micro Cap)
17.00
40
0.00%
1.91
48.31%
8.30
Total Returns (Price + Dividend) 
Kimia Bioscien. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Kimia Biosciences Ltd Valuation Shifts to Very Attractive Amid Sector Challenges
Kimia Biosciences Ltd has witnessed a marked improvement in its valuation parameters, shifting from an attractive to a very attractive rating. This change reflects a significant recalibration in price-to-earnings and price-to-book value metrics, positioning the micro-cap pharmaceutical firm favourably against its peers and historical benchmarks.
Read More
Kimia Biosciences Ltd Upgraded to Hold as Financial and Technical Trends Improve
Kimia Biosciences Ltd has seen its investment rating upgraded from Sell to Hold following a notable improvement in its financial trend and technical indicators. Despite persistent challenges in sales growth and cash flow, the company’s profitability and valuation metrics have strengthened, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.
Read More
Kimia Biosciences Ltd is Rated Strong Sell
Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 July 2026, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the stock’s current position as of 30 October 2026, providing investors with the most up-to-date analysis.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSENewspaper publication of Unaudited financial results for the Quarter ended 30 September 2026
Results-Unaudited Standalone Financial Result For Quarter Ending 30Th September 2026
13-Nov-2026 | Source : BSEUnaudited Standalone Financial Results for second quarter and half year ended 30th September 2026 along with statement of assets and liabilities and cash flows and Limited Review Report thereon.
Board Meeting Outcome for Outcome Of Board Meeting Held On November 13 2026 (Friday)
13-Nov-2026 | Source : BSEPursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we have enclosed herewith:
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (0.38%)
Held by 0 FIIs
Sameer Goel (74.94%)
Anish Kumar Aggarwal (4.33%)
22.67%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 29.39% vs -23.82% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 563.89% vs -2.70% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 13.84% vs 4.44% in Sep 2024
Growth in half year ended Sep 2025 is -46.89% vs 159.22% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 8.68% vs 8.19% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -7.35% vs 207.32% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -3.40% vs 13.39% in Mar 2025
YoY Growth in year ended Mar 2026 is -22.68% vs 280.98% in Mar 2025